



Canadian  
Cancer Clinical  
Trials Network

Réseau canadien  
d'essais cliniques  
sur le cancer

Canadian Cancer Clinical Trials Network

# 3CTN Y11Q1 Performance Report

April 1, 2024 – June 30, 2024


# Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials .....	2
Patient Recruitment at All Network Sites .....	2
Patient Access: Adolescent and Young Adult (AYA) and Remote Access Recruitment .....	3
Portfolio Trials and Accruals by Region/Site .....	4
Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Alberta, British Columbia, and Manitoba .....	4
Number of active recruiting 3CTN Portfolio trials – Alberta, British Columbia, and Manitoba .....	5
Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Ontario .....	6
Number of active recruiting 3CTN Portfolio trials – Ontario .....	7
Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Newfoundland and Quebec.....	8
Number of active recruiting 3CTN Portfolio Trials – Newfoundland and Quebec.....	9
Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Pediatric Cancer Centres.....	10
Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres .....	11
Section B: 3CTN Portfolio Metrics.....	12
Active Recruiting Portfolio Trials by Disease Site and Phase .....	12
Overview of Portfolio Applications – Process Efficiency.....	13
Trials Added to the 3CTN Portfolio in Y11Q1 (April 1 – June 30, 2024).....	14

# Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

## Patient Recruitment at All Network Sites

**Objective:** To improve patient access to academic clinical trials and improve patient recruitment by greater than 100% within five years.



**Notes:**

- 851 patients were recruited (827 to Adult and 24 to Pediatric cancer centres) to Portfolio trials in Quarter 1.
- Overall, ~26% of Adult Sites (10 out of 38) are on target to meet or exceeded their Y11 target of 90% above pre-3CTN baseline.
- \*Pediatric progress to pre-3CTN baseline recruitment is shown.

## Patient Access: Adolescent and Young Adult (AYA) and Remote Access Recruitment

**Objective:** To improve trial access and overcome barriers to trial participation for under-represented populations.

Network Site	Primary Site Remote Access Patient	Satellite Site Remote Access Patient	AYA Accrual Aged (15-39)
Sunnybrook Health Sciences Centre	0	0	2
Trillium Health Partners - Credit Valley Hospital	0	2	0
BC Cancer – Vancouver	0	0	1
BC Cancer – Prince George	0	0	1
Tom Baker Cancer Centre	0	0	1
Centre hospitalier universitaire de Sainte-Justine	0	0	2
Montreal Children’s Hospital	0	0	1
Children’s Hospital of Eastern Ontario	0	0	1
IWK Health Centre	1	0	0
Jim Pattison Children’s Hospital	1	0	0
Stollery Children’s Hospital	0	0	1
The Hospital for Sick Children	2	0	0
<b>Total</b>	<b>4</b>	<b>2</b>	<b>10</b>

\*Table excludes remote access patients recruited through the Canadian Remote Access Framework for Clinical Trials (CRAFT) proof of concept project. Numbers based on date of remote access initiation.

## Portfolio Trials and Accruals by Region/Site

Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Alberta, British Columbia, and Manitoba

Network Site	Pre-3CTN Baseline	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10 Total	Y11		
							Q1	% of Baseline	% of Target
CancerCare Manitoba	99	51	44	59	90	58	10	10%	5%
Western Manitoba Cancer Centre	1	1	0	1	4	1	0	0%	0%
<b>Manitoba Total</b>	<b>100</b>	<b>51</b>	<b>44</b>	<b>60</b>	<b>94</b>	<b>59</b>	<b>10</b>	<b>10%</b>	<b>5%</b>
BC Cancer – Vancouver	106	110	154	175	203	148	25	24%	12%
BC Cancer – Abbotsford	16	1	1	2	8	7	2	13%	7%
BC Cancer – Prince George	1	10	14	21	13	9	3	300%	158%
BC Cancer – Kelowna	38	33	36	35	56	66	12	32%	17%
BC Cancer – Victoria	26	78	40	42	35	73	9	35%	18%
BC Cancer – Surrey	44	0	0	0	21	27	3	7%	4%
<b>British Columbia Total</b>	<b>231</b>	<b>232</b>	<b>245</b>	<b>275</b>	<b>336</b>	<b>330</b>	<b>54</b>	<b>23%</b>	<b>12%</b>
Cross Cancer Institute	102	310	202	118	0	65	13	13%	7%
Tom Baker Cancer Centre	76	341	248	166	0	61	7	9%	5%
<b>Alberta Total</b>	<b>178</b>	<b>651</b>	<b>450</b>	<b>284</b>	<b>0</b>	<b>126</b>	<b>20</b>	<b>11%</b>	<b>6%</b>
<b>Western Region Total</b>	<b>509</b>	<b>934</b>	<b>739</b>	<b>619</b>	<b>430</b>	<b>515</b>	<b>84</b>	<b>17%</b>	<b>9%</b>

Number of active recruiting 3CTN Portfolio trials – Alberta, British Columbia, and Manitoba

Network Site	Pre-3CTN Baseline	Y8 (2021-22)				Y9 (2022-23)				Y10 (2023-24)				Y11 (2024-25)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
CancerCare Manitoba	37	17	17	15	15	17	17	16	17	19	14	15	14	14			
Western Manitoba Cancer Centre	0	1	1	2	2	2	2	2	2	2	2	2	2	2			
BC Cancer – Vancouver	50	29	27	29	30	31	40	40	43	44	44	46	35	38			
BC Cancer – Abbotsford	6	0	1	1	2	2	3	2	2	2	2	3	4	3			
BC Cancer – Prince George	2	6	5	5	8	3	4	5	5	5	5	6	10	7			
BC Cancer – Kelowna	23	8	8	8	4	10	10	10	11	11	11	16	17	14			
BC Cancer – Victoria	12	11	8	9	10	11	9	9	9	13	13	15	18	15			
BC Cancer – Surrey	6	-	-	-	-	7	7	7	7	7	6	6	8	5			
Cross Cancer Institute	29	25	22	22	22	-	-	-	-	19	19	32	23	16			
Tom Baker Cancer Centre	20	23	25	25	22	-	-	-	-	29	27	23	32	21			

Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Ontario

Network Site	Pre-3CTN Baseline	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10 Total	Y11		
							Q1	% of Baseline	% of Target
London Health Sciences Centre	186	942	693	656	506	695	154	83%	44%
Grand River Regional Cancer Centre	20	19	24	23	58	32	1	5%	3%
Windsor Regional Cancer Centre	14	3	2	3	2	11	0	0%	0%
Juravinski Cancer Centre	181	217	142	190	136	170	39	22%	11%
Cambridge Memorial Hospital	11	8	9	11	6	0	0	0%	0%
St. Joseph's Healthcare Hamilton	21	20	54	87	56	23	0	0%	0%
Walker Family Cancer Centre	17	40	7	23	38	13	3	18%	9%
Oakville Trafalgar Memorial Hospital	1	-	-	-	0	0	0	0%	0%
Sunnybrook Health Sciences Centre	141	638	395	671	593	708	289	205%	108%
Humber River Health	1	3	4	2	14	32	7	700%	368%
Michael Garron Hospital	2	0	0	0	0	0	0	0%	0%
Princess Margaret Cancer Centre	396	543	267	338	390	488	67	17%	9%
Markham Stouffville Hospital	1	6	3	0	6	1	1	100%	53%
Mount Sinai Hospital	21	7	67	543	121	2	1	5%	3%
Northeast Cancer Centre	24	17	7	2	5	8	0	0%	0%
North York General Hospital	1	7	7	10	21	5	4	400%	211%
Royal Victoria Regional Health Centre	8	25	13	44	37	27	7	88%	46%
St. Michael's Hospital	19	3	0	9	1	17	1	5%	3%
Southlake Regional Health Centre	10	32	9	13	9	13	2	20%	11%
Thunder Bay Regional Health Sciences Centre	26	4	2	39	22	19	6	23%	12%
Trillium Health Partners - Credit Valley Hospital	27	10	2	10	12	23	2	7%	4%
William Osler Health System	1	16	2	3	6	4	0	0%	0%
The Ottawa Hospital Cancer Centre	132	804	483	771	830	570	115	87%	46%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	89	59	52	48	37	17	41%	22%
R.S. McLaughlin Durham Regional Cancer Centre	22	36	3	7	26	16	14	64%	33%
<b>Central Region Total</b>	<b>1324</b>	<b>3489</b>	<b>2254</b>	<b>3507</b>	<b>2943</b>	<b>2914</b>	<b>730</b>	<b>55%</b>	<b>29%</b>

Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)				Y11 (2024-25)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
London Health Sciences Centre	79	42	38	39	36	32	29	31	29	30	27	29	46	28			
Grand River Regional Cancer Centre	11	6	7	7	8	11	11	11	11	10	10	10	12	6			
Windsor Regional Cancer Centre	4	2	2	2	2	8	3	3	3	3	3	4	8	4			
Juravinski Cancer Centre	51	38	31	35	37	36	29	27	27	36	25	21	27	20			
Cambridge Memorial Hospital	5	2	3	3	2	2	2	2	2	2	0	0	0	0			
St. Joseph's Healthcare Hamilton	2	2	2	2	2	2	2	2	2	2	2	2	3	2			
Walker Family Cancer Centre	10	6	6	6	8	8	8	8	7	7	7	7	5	6			
Oakville Trafalgar Memorial Hospital		-	-	-	-	0	0	0	0	0	0	0	0	0			
Sunnybrook Health Sciences Centre	10	32	30	35	40	45	48	48	53	50	48	49	41	56			
Humber River Health	0	1	0	2	1	0	1	1	1	1	1	1	3	1			
Michael Garron Hospital	3	1	1	1	1	1	1	1	1	0	0	0	0	0			
Princess Margaret Cancer Centre	91	68	68	66	64	73	74	74	75	81	78	81	93	97			
Markham Stouffville Hospital	0	0	0	1	1	2	2	2	2	1	1	2	3	1			
Mount Sinai Hospital	6	3	2	3	3	3	3	3	4	4	4	4	2	4			
Northeast Cancer Centre	10	9	9	9	9	9	9	9	11	10	10	9	6	9			
North York General Hospital	0	4	5	5	5	5	5	5	3	3	1	1	2	2			
Royal Victoria Regional Health Centre	5	12	13	11	11	12	12	12	12	12	11	12	9	14			
St. Michael's Hospital	4	1	1	2	1	1	1	1	1	2	2	2	7	4			
Southlake Regional Health Centre	3	8	7	9	9	9	9	9	9	9	8	8	3	12			
Thunder Bay Regional Health Sciences Centre	8	2	3	4	5	4	4	5	5	4	5	6	7	2			
Trillium Health Partners - Credit Valley Hospital	9	6	6	6	7	7	6	6	6	6	6	6	9	6			
William Osler Health System	0	2	2	1	2	2	2	2	2	2	2	2	2	2			
The Ottawa Hospital Cancer Centre	56	37	43	44	43	39	37	38	38	38	34	33	42	35			
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	21	21	23	24	21	20	20	18	19	18	17	17	20			
R.S. McLaughlin Durham Regional Cancer Centre	13	3	3	4	3	6	8	8	8	8	5	7	14	12			



Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Newfoundland and Quebec

Network Site	Pre-3CTN Baseline	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10 Total	Y11		
							Q1	% of Baseline	% of Target
Eastern Regional Health Authority	15	16	5	10	17	11	4	27%	14%
Atlantic Total	15	36	5	10	17	11	4	27%	14%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	155	90	156	127	92	0	0%	0%
CHU de Québec – Université Laval, adults	180	309	372	456	198	170	9	5%	3%
Quebec Total	267	464	462	612	325	262	9	3%	2%
<b>Eastern Region Total</b>	<b>282</b>	<b>500</b>	<b>467</b>	<b>622</b>	<b>342</b>	<b>273</b>	<b>13</b>	<b>3%</b>	<b>1%</b>

## Number of active recruiting 3CTN Portfolio Trials – Newfoundland and Quebec

Network Site	Pre-3CTN Baseline	Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)				Y11 (2024-25)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Eastern Regional Health Authority	6	9	8	8	6	5	5	6	5	5	4	3	7	5			
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	29	28	27	21	21	22	22	22	29	27	27	17	29			
CHU de Québec – Université Laval, adults	39	31	34	31	30	31	30	29	28	32	30	30	28	39			

Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10 Total	Y11	
							Q1	% of Baseline
BC Children's Hospital	34	-	30	24	19	16	2	6%
CancerCare Manitoba – Pediatrics	18	7	12	6	9	10	2	11%
Centre hospitalier universitaire de Sainte-Justine	42	38	51	54	21	24	4	10%
Children's Hospital - London Health Sciences Centre	12	-	5	5	14	4	0	0%
Children's Hospital of Eastern Ontario	20	-	14	16	16	17	3	15%
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	17	21	29	26	18	12	1	6%
IWK Health Centre	20	-	6	11	9	8	2	10%
Janeway Children's Health and Rehabilitation Centre	4	0	5	2	5	0	1	25%
Jim Pattison Children's Hospital	6	-	7	3	4	4	1	17%
McMaster Children's Hospital - Hamilton Health Sciences Centre	14	-	16	24	16	4	3	21%
Montreal Children's Hospital	24	10	16	20	13	6	2	8%
Stollery Children's Hospital	11	-	20	23	11	9	1	9%
The Hospital for Sick Children	91	-	26	73	43	17	2	2%
<b>Pediatric Total</b>	<b>313</b>	<b>76</b>	<b>256</b>	<b>301</b>	<b>198</b>	<b>131</b>	<b>24</b>	<b>8%</b>


## Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)				Y11 (2024-25)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
BC Children's Hospital	15	17	17	17	17	18	19	19	19	20	19	20	17	22			
CancerCare Manitoba - Pediatrics	19	14	16	16	20	20	20	21	21	22	22	24	28	21			
Centre hospitalier universitaire de Sainte-Justine	9	22	27	29	27	29	24	22	24	29	24	26	36	26			
Children's Hospital - London Health Sciences Centre	5	16	16	14	18	17	16	16	16	17	16	16	14	8			
Children's Hospital of Eastern Ontario	8	16	14	16	16	17	17	17	22	17	14	13	19	8			
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	11	21	20	22	23	19	24	23	22	24	21	22	25	16			
IWK Health Centre	9	20	19	21	23	25	25	26	26	30	29	31	25	35			
Janeway Children's Health and Rehabilitation Centre	5	10	13	10	9	10	10	10	10	11	13	11	11	13			
Jim Pattison Children's Hospital	7	8	7	7	8	8	8	8	8	8	8	8	10	11			
McMaster Children's Hospital - Hamilton Health Sciences Centre	8	17	20	20	24	25	25	25	25	25	25	25	14	25			
Montreal Children's Hospital	5	22	24	25	26	27	30	30	27	28	27	24	33	22			
Stollery Children's Hospital	3	14	13	12	13	15	15	15	16	17	16	16	20	22			
The Hospital for Sick Children	13	24	30	27	28	28	27	27	27	29	31	30	34	31			

## Section B: 3CTN Portfolio Metrics

### Active Recruiting Portfolio Trials by Disease Site and Phase

**Objective:** To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



## Overview of Portfolio Applications – Process Efficiency

**Objective:** To improve Portfolio application processing time.

### Portfolio Approval Process Timeline<sup>1</sup>

Calendar Year	Number of Applications Received	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2017	45	47	22	6
2018	46	44	18	5
2019	45	45	42	3
2020	41	41	27	0
2021	59	63	29	1
2022	36	33	3	0
2023	41	42	12	0
2024	27	27	5	0

### Facilitated Peer Review (FPR) Process

Calendar Year	Number of FPR Requests	# FPR Completed <sup>2</sup>	Average FPR Time (days) <sup>3</sup>	Median FPR Time (days) <sup>3</sup>
2017	4	5	79	74
2018	10	7	84	77
2019	16	17	112	86
2020	7	6	137	134
2021	9	13	112	108
2022	3	1	44	44
2023	6	7	63	58
2024	2	3	40	36

<sup>1</sup> From Portfolio application receipt date to date of approval decision for period beginning Jan 13, 2015.

<sup>2</sup> Counts are based on the completed reviews in that calendar year. E.g., for an application submitted for review in 2019 but completed in 2020, the FPR will be counted for 2020.

<sup>3</sup> FPR process begins on the date the applicant agrees to initiate the FPR process and ends on the date when the final reviewer package is submitted to 3CTN (data based on completed FPRs).

Link: [Portfolio Applications Report](#)

## Trials Added to the 3CTN Portfolio in Y11Q1 (April 1 – June 30, 2024)

Trial short title	Trial phase	Disease site	Complexity rating	Trial link
(CCTG) CE.9 / LUMOS2	Phase II	Brain/CNS	High	<a href="https://clinicaltrials.gov/ct2/show/study/ACTRN12623000096651">ACTRN12623000096651</a>
(CCTG) MAC.29 / Alliance A012103	Phase III	Breast	Low	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05812807">NCT05812807</a>
(CCTG) CO.32 NEO-RT	Phase III	Gastrointestinal	High	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06205485">NCT06205485</a>
(Maastricht University) NL80303.068.22 / DRAGON 2	Not Applicable	Gastrointestinal	Low	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05428735">NCT05428735</a>
(CCTG) PR.24 / ASCENDE-SBRT	Phase III	Genito-Urinary	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06235697">NCT06235697</a>
(CHUQ) PCS XI	Phase III	Genito-Urinary	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05820633">NCT05820633</a>
(CCTG) MY.13	Phase III	Hematology	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06182774">NCT06182774</a>
(COG) ASCT2031	Phase III	Hematology	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05457556">NCT05457556</a>
(COG) ANBL2131	Phase III	Neuroblastoma	High	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06172296">NCT06172296</a>

Link: [3CTN's Portfolio Trial Listing](#)